Hamdouchi C, de Blas J, del Prado M, Gruber J, Heinz B A, Vance L
Centro de Investigación Lilly, S.A., Avenida de la Industria, 30, 28108 Alcobendas, Madrid, Spain.
J Med Chem. 1999 Jan 14;42(1):50-9. doi: 10.1021/jm9810405.
A series of 2-amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]+ ++imid azo[1,2-a]pyridines 1a-i, structurally related to Enviroxime and its analogous benzimidazoles, was designed and prepared for testing as antirhinovirus agents. The imidazo ring in this class of compounds was constructed starting from the aminopyridine after tosylation and subsequent treatment with the appropriate acetamides. The key steps in the synthesis include the development and use of a new Horner-Emmons reagent for the direct incorporation of methyl vinylcarboxamide. The reaction was stereospecific in the substrates 5a-f leading exclusively to the desired E-isomer and avoiding the use of reverse-phase preparative HPLC for the separation of both possible isomers before antiviral activity evaluation. The isopropylsulfonyl group, known as the best substituent at the 1-position in the benzimidazole SAR in terms of activity, was introduced in this new series of imidazo[1,2-a]pyridines via halogen-metal exchange and subsequent treatment with isopropyl isopropanethiolsulfonate. Compounds 1a-i were evaluated in plaque reduction assay and in a cytopathic effect assay. Compounds 1b-d,h exhibited a strong antirhinovirus activity, and no apparent cellular toxicity was visible. The substitution at the 3-position was required for activity. Surprisingly the isopropylsulfonyl in this family of compounds did not enhance the activity as in the case of benzimidazoles. Instead, compound 1i was 4 times less active than its phenyl and sulfide partners. The chemistry as well as the biological evaluation are discussed.
设计并制备了一系列2-氨基-3-取代-6-[(E)-1-苯基-2-(N-甲基氨基甲酰基)乙烯基]咪唑并[1,2-a]吡啶1a-i,其结构与Enviraxime及其类似的苯并咪唑相关,用于作为抗鼻病毒剂进行测试。这类化合物中的咪唑环是从氨基吡啶经甲苯磺酰化并随后用适当的乙酰胺处理后构建的。合成中的关键步骤包括开发和使用一种新的霍纳尔-埃蒙斯试剂以直接引入甲基乙烯基甲酰胺。该反应在底物5a-f中具有立体专一性,仅生成所需的E-异构体,避免了在抗病毒活性评估前使用反相制备型高效液相色谱法分离两种可能的异构体。在苯并咪唑构效关系中,异丙基磺酰基在1-位被认为是活性方面最佳的取代基,在这一系列新的咪唑并[1,2-a]吡啶中通过卤代-金属交换并随后用异丙基异丙硫醇磺酸酯处理引入。化合物1a-i在蚀斑减少试验和细胞病变效应试验中进行了评估。化合物1b-d、h表现出很强的抗鼻病毒活性,且未见明显的细胞毒性。3-位的取代是活性所必需的。令人惊讶的是,在这类化合物中异丙基磺酰基并未像在苯并咪唑的情况那样增强活性。相反,化合物1i的活性比其苯基和硫化物类似物低4倍。讨论了化学合成以及生物学评估。